Cargando…
Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity
Mannitol infusion is commonly used in the treatment of intracranial hypertension following traumatic brain injury. It has long been known to have stability issues, specifically, mannitol recrystallises from solutions greater than 10% w/v in ambient conditions. This can happen at any time, whether on...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076636/ https://www.ncbi.nlm.nih.gov/pubmed/32098214 http://dx.doi.org/10.3390/pharmaceutics12020187 |
_version_ | 1783507252949286912 |
---|---|
author | Kavanagh, Oisín Hogan, Fiona Murphy, Caoimhe Croker, Denise Walker, Gavin |
author_facet | Kavanagh, Oisín Hogan, Fiona Murphy, Caoimhe Croker, Denise Walker, Gavin |
author_sort | Kavanagh, Oisín |
collection | PubMed |
description | Mannitol infusion is commonly used in the treatment of intracranial hypertension following traumatic brain injury. It has long been known to have stability issues, specifically, mannitol recrystallises from solutions greater than 10% w/v in ambient conditions. This can happen at any time, whether on the pharmacy shelf or during a medical procedure. This study describes the stability limits of 20% w/v mannitol infusion (the most common strength used clinically) and proposes a number of safer, stable and tuneable hyperosmotic formulations of mannitol in combination with clinically acceptable osmotic agents (NaCl, sorbitol and glycerol). |
format | Online Article Text |
id | pubmed-7076636 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70766362020-03-20 Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity Kavanagh, Oisín Hogan, Fiona Murphy, Caoimhe Croker, Denise Walker, Gavin Pharmaceutics Communication Mannitol infusion is commonly used in the treatment of intracranial hypertension following traumatic brain injury. It has long been known to have stability issues, specifically, mannitol recrystallises from solutions greater than 10% w/v in ambient conditions. This can happen at any time, whether on the pharmacy shelf or during a medical procedure. This study describes the stability limits of 20% w/v mannitol infusion (the most common strength used clinically) and proposes a number of safer, stable and tuneable hyperosmotic formulations of mannitol in combination with clinically acceptable osmotic agents (NaCl, sorbitol and glycerol). MDPI 2020-02-21 /pmc/articles/PMC7076636/ /pubmed/32098214 http://dx.doi.org/10.3390/pharmaceutics12020187 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Kavanagh, Oisín Hogan, Fiona Murphy, Caoimhe Croker, Denise Walker, Gavin Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity |
title | Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity |
title_full | Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity |
title_fullStr | Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity |
title_full_unstemmed | Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity |
title_short | Formulating a Stable Mannitol Infusion while Maintaining Hyperosmolarity |
title_sort | formulating a stable mannitol infusion while maintaining hyperosmolarity |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7076636/ https://www.ncbi.nlm.nih.gov/pubmed/32098214 http://dx.doi.org/10.3390/pharmaceutics12020187 |
work_keys_str_mv | AT kavanaghoisin formulatingastablemannitolinfusionwhilemaintaininghyperosmolarity AT hoganfiona formulatingastablemannitolinfusionwhilemaintaininghyperosmolarity AT murphycaoimhe formulatingastablemannitolinfusionwhilemaintaininghyperosmolarity AT crokerdenise formulatingastablemannitolinfusionwhilemaintaininghyperosmolarity AT walkergavin formulatingastablemannitolinfusionwhilemaintaininghyperosmolarity |